Millennium Management’s VanEck Biotech ETF BBH Stock Holding History

Millennium Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,162	Closed	-$638K	–	6776
2021 Q2	$638K	Buy	+3,162	New	+$589K	﹤0.01%	5091
2016 Q4	–	Sell	-11,160	Closed	-$1.29M	–	3324
2016 Q3	$1.29M	Sell	11,160 -7,317	-40%	-$834K	﹤0.01%	2151
2016 Q2	$1.89M	Buy	18,477 +7,102	+62%	+$757K	﹤0.01%	1814
2016 Q1	$1.18M	Buy	11,375 +7,424	+188%	+$774K	﹤0.01%	2094
2015 Q4	$502K	Sell	3,951 -1,963	-33%	-$240K	﹤0.01%	2642
2015 Q3	$676K	Buy	+5,914	New	+$783K	﹤0.01%	2495
2015 Q2	–	Sell	-3,336	Closed	-$432K	–	3314
2015 Q1	$432K	Buy	+3,336	New	+$419K	﹤0.01%	2829

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Millennium Management's BBH Position: Q3 2021 in Review

Millennium Management sold out of VanEck Biotech ETF (BBH) in Q3 2021, closing a stake of 3,162 shares — an estimated $638K sold.

Millennium Management first reported a position in BBH in Q1 2015 and held it in 7 quarters. The position peaked at $1.89M in Q2 2016. 118 funds tracked by Wall St. Rank hold BBH as of Q3 2021.

Millennium Management reported no remaining VanEck Biotech ETF position as of Q3 2021 after selling out during the quarter.
Millennium Management sold 3,162 VanEck Biotech ETF shares in Q3 2021, an estimated $638K.
Millennium Management first reported a position in VanEck Biotech ETF in Q1 2015 and held it in 7 quarters.
Millennium Management's VanEck Biotech ETF position peaked at $1.89M in Q2 2016.
118 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2021.

Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.